WO2002040665A3 - Complementing cell lines - Google Patents

Complementing cell lines Download PDF

Info

Publication number
WO2002040665A3
WO2002040665A3 PCT/NL2001/000824 NL0100824W WO0240665A3 WO 2002040665 A3 WO2002040665 A3 WO 2002040665A3 NL 0100824 W NL0100824 W NL 0100824W WO 0240665 A3 WO0240665 A3 WO 0240665A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell lines
human
adenovirus
primary
cell line
Prior art date
Application number
PCT/NL2001/000824
Other languages
French (fr)
Other versions
WO2002040665A2 (en
Inventor
Ronald Vogels
Menzo Jans Emco Havenga
Majid Mehtali
Original Assignee
Crucell Holland Bv
Ronald Vogels
Menzo Jans Emco Havenga
Majid Mehtali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Ronald Vogels, Menzo Jans Emco Havenga, Majid Mehtali filed Critical Crucell Holland Bv
Priority to AU2002218569A priority Critical patent/AU2002218569B2/en
Priority to AU1856902A priority patent/AU1856902A/en
Priority to EP01996603A priority patent/EP1349926B1/en
Priority to NZ525997A priority patent/NZ525997A/en
Priority to SI200130627T priority patent/SI1349926T1/en
Priority to DE60121471T priority patent/DE60121471T2/en
Priority to CA2428739A priority patent/CA2428739C/en
Priority to JP2002543660A priority patent/JP4402881B2/en
Publication of WO2002040665A2 publication Critical patent/WO2002040665A2/en
Publication of WO2002040665A3 publication Critical patent/WO2002040665A3/en
Priority to CY20061101321T priority patent/CY1105232T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Abstract

A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells (e.g., primary human retinoblasts, primary human embryonic kidney cells and primary human amniocytes) which are transformed by adenovirus E1 sequences. Also disclosed is a cell line derived from PER.C6 (ECACC deposit number 96022940), which cell expresses functional Ad35 E1B sequences. The new cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, measles virus.
PCT/NL2001/000824 2000-11-15 2001-11-14 Complementing cell lines WO2002040665A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2002218569A AU2002218569B2 (en) 2000-11-15 2001-11-14 Complementing cell lines
AU1856902A AU1856902A (en) 2000-11-15 2001-11-14 Complementing cell lines
EP01996603A EP1349926B1 (en) 2000-11-15 2001-11-14 Complementing cell lines
NZ525997A NZ525997A (en) 2000-11-15 2001-11-14 Packaging cell lines for subgroup B recombinant adenoviruses
SI200130627T SI1349926T1 (en) 2000-11-15 2001-11-14 Complementing cell lines
DE60121471T DE60121471T2 (en) 2000-11-15 2001-11-14 COMPLEMENTING CELL LINES
CA2428739A CA2428739C (en) 2000-11-15 2001-11-14 Complementing cell lines
JP2002543660A JP4402881B2 (en) 2000-11-15 2001-11-14 Complementary cell lines
CY20061101321T CY1105232T1 (en) 2000-11-15 2006-09-15 COMPLEMENTATION CELL LINES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/713,678 2000-11-15
US09/713,678 US6492169B1 (en) 1999-05-18 2000-11-15 Complementing cell lines

Publications (2)

Publication Number Publication Date
WO2002040665A2 WO2002040665A2 (en) 2002-05-23
WO2002040665A3 true WO2002040665A3 (en) 2002-10-17

Family

ID=24867049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2001/000824 WO2002040665A2 (en) 2000-11-15 2001-11-14 Complementing cell lines

Country Status (13)

Country Link
US (8) US6492169B1 (en)
EP (1) EP1349926B1 (en)
JP (1) JP4402881B2 (en)
AT (1) ATE332965T1 (en)
AU (2) AU2002218569B2 (en)
CA (1) CA2428739C (en)
CY (1) CY1105232T1 (en)
DE (1) DE60121471T2 (en)
DK (1) DK1349926T3 (en)
ES (1) ES2267864T3 (en)
NZ (1) NZ525997A (en)
PT (1) PT1349926E (en)
WO (1) WO2002040665A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE278794T1 (en) * 1995-06-15 2004-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRUSES, FOR USE IN GENE THERAPY
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
WO2003048348A2 (en) * 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
US7235233B2 (en) * 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
DK1497440T3 (en) 2002-04-25 2008-12-01 Crucell Holland Bv Stable adenoviral vectors and methods of propagation thereof
PT1497438E (en) * 2002-04-25 2010-02-04 Crucell Holland Bv Means and methods for the production of adenovirus vectors
US20060073123A1 (en) * 2002-04-30 2006-04-06 Jie Mi Adenovirus vectors for immunotherapy
JP4237449B2 (en) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 Adenovirus vector
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) * 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US9388427B2 (en) * 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
EP1611237A1 (en) * 2003-03-28 2006-01-04 Merck & Co., Inc. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
KR101183770B1 (en) 2003-05-09 2012-09-17 크루셀 홀란드 비.브이. Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom
DE602004027483D1 (en) * 2003-05-23 2010-07-15 Crucell Holland Bv PREPARATION OF RECOMBINANT IGM IN THE PER.C6 CELLS
AU2004260044B2 (en) * 2003-07-18 2009-04-23 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
DK1648931T3 (en) 2003-07-21 2011-03-07 Transgene Sa Multifunctional cytokines
WO2005033320A1 (en) 2003-10-02 2005-04-14 Crucell Holland B.V. Packaging cells for recombinant adenovirus
DE602005015332D1 (en) * 2004-02-23 2009-08-20 Crucell Holland Bv Method for cleaning viruses
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7608425B2 (en) 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
KR101253363B1 (en) 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 Improved adenoviral vectors and uses thereof
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
US7510719B2 (en) 2004-12-08 2009-03-31 Medimmune, Llc Methods of producing influenza vaccine compositions
AU2012216357B2 (en) * 2005-04-11 2014-01-30 Purdue Research Foundation Vaccine against pandemic strains of influenza viruses
WO2006108707A1 (en) * 2005-04-11 2006-10-19 Crucell Holland B.V. Virus purification using ultrafiltration
AU2006249877A1 (en) * 2005-05-23 2006-11-30 Vaxin, Inc. Rapid production of adenovirus-free recombinant adenovirus vectors
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
PL2301572T3 (en) 2005-11-01 2015-02-27 Novartis Influenza Vaccines Marburg Gmbh Cell-derived viral vaccines with low levels of residual cell dna
DE102005054628A1 (en) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Process for the preparation of permanent human cell lines
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
DK2029168T3 (en) 2006-06-02 2013-01-14 Int Aids Vaccine Initiative HIV-1 Clade A consensus sequences, antigens and transgenes.
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
CN101617052A (en) 2007-01-30 2009-12-30 特兰斯吉恩股份有限公司 The papilloma virus E2 polypeptide that is used for immunity
WO2008112540A2 (en) * 2007-03-09 2008-09-18 Vectorlogics, Inc. Cells for adenovirus vector and protein production
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2342321B1 (en) 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
WO2010060719A1 (en) * 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
EP2382474B1 (en) 2009-01-20 2015-03-04 Transgene SA Soluble icam-1 as biomarker for prediction of therapeutic response
KR20110138354A (en) 2009-03-24 2011-12-27 트랜스진 에스.에이. Biomarker for monitoring patients
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
CN102483405B (en) 2009-07-10 2015-12-02 特朗斯吉有限公司 For selecting biomarker and the correlation technique of patient
NZ598000A (en) 2009-08-07 2013-10-25 Transgene Sa Composition for treating hbv infection
EA028875B1 (en) 2009-10-15 2018-01-31 Янссен Вэксинс Энд Превеншн Б.В. Method for purifying adenovirus particles from a cell suspension
KR101749779B1 (en) 2009-10-15 2017-06-21 크루셀 홀란드 비.브이. Method for the purification of adenovirus particles
JP2013507990A (en) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション High-titer recombinant influenza virus with enhanced replication in Vero cells
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
EA023816B1 (en) 2010-02-15 2016-07-29 Круселл Холланд Б.В. METHOD FOR THE PRODUCTION OF Ad26 VIRUS PARTICLES
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2563909A1 (en) 2010-04-26 2013-03-06 Novartis AG Improved production of virus replicon particles in packaging cells
ES2524894T3 (en) * 2010-08-16 2014-12-15 Cevec Pharmaceuticals Gmbh Permanent human amniocyte cell line for influenza virus production
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013008700B8 (en) 2010-10-11 2022-10-04 Novartis Ag SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
US9058175B2 (en) * 2011-06-07 2015-06-16 The Mathworks, Inc. Parameter promotion in a block diagram modeling environment
CA2872033A1 (en) 2011-10-11 2013-04-18 Novartis Ag Recombinant self-replicating polycistronic rna molecules
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
EA034284B1 (en) 2012-03-12 2020-01-24 Янссен Вэксинс Энд Превеншн Б.В. Particles of recombinant transgene containing adenovirus with 5' terminal nucleotides ctatctat
BR112014023196B1 (en) 2012-03-22 2021-09-08 Janssen Vaccines & Prevention B.V. VACCINES AGAINST RESPIRATORY SYNCYCIAL VIRUS (RSV), ITS METHOD OF PRODUCTION, AND ISOLATED RECOMBINANT NUCLEIC ACID
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
US9442702B1 (en) 2012-04-30 2016-09-13 The Mathworks, Inc. Overriding an interface in a graphical block diagram modeling environment
WO2013174910A1 (en) 2012-05-24 2013-11-28 Crucell Holland B.V. Adenoviral vectors for transduction of vascular tissue
CN104870477B (en) 2012-10-23 2018-10-09 爱默蕾大学 GM-CSF and IL-4 conjugates, composition and relative method
CA3200425A1 (en) 2012-11-16 2014-05-22 Peter ABBINK Recombinant adenoviruses and use thereof
CN105188745B (en) 2013-04-25 2019-10-18 扬森疫苗与预防公司 RSV F polypeptide before stabilized soluble fusion
BR112015031509B1 (en) 2013-06-17 2023-05-09 Janssen Vaccines & Prevention B.V. RESPIRATORY SYNCYTIAL VIRUS (RSV) FUSION POLYPEPTIDE (F) RECOMBINANT PRE-FUSION AND COMPOSITION INCLUDING IT
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
EP3046536B1 (en) 2013-09-19 2018-11-28 Janssen Vaccines & Prevention B.V. Improved adenovirus formulations
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (en) 2013-12-20 2017-02-22 博德研究所 Combination therapy with neoantigen vaccine
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MA40920A (en) 2014-11-07 2017-09-12 Takeda Vaccines Inc VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
EP3268044A2 (en) 2015-03-11 2018-01-17 The Broad Institute Inc. Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
PL3283634T3 (en) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CR20230191A (en) 2015-05-20 2023-07-06 Dana Farber Cancer Inst Inc SHARED NEOANTIGENS (Div. exp 2017-584)
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
TW202241500A (en) 2015-06-09 2022-11-01 美商博德研究所有限公司 Formulations for neoplasia vaccines and methods of preparing thereof
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
BR112017028449A2 (en) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv stabilized soluble rsv f polypeptides
JP7189014B2 (en) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Vaccine against RSV
EA036412B1 (en) 2015-10-06 2020-11-09 Янссен Вэксинс Энд Превеншн Б.В. Method for protecting an adenovirus from plastic-induced degradation and use of 2-hydroxypropyl--cyclodextrin for protecting the adenovirus
WO2017143236A1 (en) 2016-02-19 2017-08-24 Yoshihiro Kawaoka Improved influenza b virus replication for vaccine development
MY193584A (en) 2016-04-05 2022-10-19 Janssen Vaccines & Prevention Bv Vaccine against rsv
KR20220041966A (en) 2016-04-05 2022-04-01 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble pre-fusion rsv f proteins
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
MY194419A (en) 2016-05-30 2022-11-30 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
MX2018015540A (en) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Potent and balanced bidirectional promoter.
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US20200096521A1 (en) 2017-02-12 2020-03-26 Neon Therapeutics, Inc. Hla-based methods and compositions and uses thereof
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
KR20200053518A (en) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Method for safe induction of immunity to RSV
EP3703739A2 (en) 2017-11-03 2020-09-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
US11773142B2 (en) 2017-12-11 2023-10-03 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
CN108342362A (en) * 2018-01-31 2018-07-31 武汉枢密脑科学技术有限公司 A kind of stable cell lines MDCK and its construction method for expanding recombination hepatitis infectiosa canis virus CAV2
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020132586A1 (en) 2018-12-21 2020-06-25 Neon Therapeutics, Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
JP2022527235A (en) 2019-01-23 2022-06-01 義裕 河岡 Mutations that impart genetic stability to additional genes in influenza virus
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
BR112021019845A2 (en) 2019-05-08 2022-02-15 Takeda Vaccines Inc Inactivated virus compositions and Zika vaccine formulations
CN113924113A (en) 2019-05-15 2022-01-11 扬森疫苗与预防公司 Co-administration of seasonal influenza vaccine with adenovirus-based respiratory syncytial virus vaccine
AU2020275910A1 (en) 2019-05-15 2021-11-04 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
EP4022046A2 (en) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
AU2021400424A1 (en) 2020-12-14 2023-07-06 Biontech Us Inc. Tissue-specific antigens for cancer immunotherapy
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2023239928A1 (en) * 2022-06-09 2023-12-14 CHO Plus Inc. Cell hybrids as host cells for high efficiency production of gene therapy vectors and viral vaccines
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000326A1 (en) * 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1998017783A1 (en) * 1996-10-23 1998-04-30 Regents Of The University Of Michigan Improved adenovirus vectors
US5880102A (en) * 1995-01-17 1999-03-09 Duke University Adenoviral vector system
DE19754103A1 (en) * 1997-12-08 1999-06-10 Hepavec Ag Fuer Gentherapie New packaging cell line for E1-deleted adenovirus
WO1999032647A1 (en) * 1997-12-23 1999-07-01 Introgene B.V. Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
DE19807265A1 (en) * 1998-02-20 1999-08-26 Centeon Pharma Gmbh New adenoviral vector useful for gene therapy
DE19918023A1 (en) * 1999-03-16 2000-09-21 Guenter Cichon Preparation of a liver cell-derived packaging cell line comprises stabile transfection of adenoviral E1 sequences of human hepatoma cells

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4487829A (en) 1982-03-23 1984-12-11 Massachusetts Institute Of Technology Production and use of monoclonal antibodies against adenoviruses
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
FR2602790B1 (en) 1986-08-13 1990-06-01 Transgene Sa EXPRESSION OF A SPECIFIC TUMOR ANTIGEN BY A RECOMBINANT VECTOR VIRUS AND USE THEREOF FOR THE PREVENTIVE OR CURATIVE TREATMENT OF THE CORRESPONDING TUMOR
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5204445A (en) 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5223394A (en) 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
DE69033181T2 (en) 1989-10-20 1999-10-21 Dartmouth College IGA RECEPTOR-SPECIFIC MONOCLONAL ANTIBODIES
CA2069960C (en) 1989-10-20 2004-03-02 Michael W. Fanger Bispecific heteroantibodies with dual effector functions
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5246921A (en) 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
GB2246779B (en) 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
JP3534749B2 (en) 1991-08-20 2004-06-07 アメリカ合衆国 Adenovirus-mediated gene transfer into the gastrointestinal tract
FR2681786A1 (en) 1991-09-27 1993-04-02 Centre Nat Rech Scient RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS.
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
AU692423B2 (en) 1992-09-25 1998-06-11 Institut National De La Sante Et De La Recherche Medicale Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0668913B1 (en) 1992-11-18 2002-01-30 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
AU6133394A (en) 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
DE4311651A1 (en) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
ES2180579T3 (en) 1993-05-10 2003-02-16 Univ Michigan TRANSFER OF GENES IN PANCREATIC EPITHELIAL CELLS.
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
EP0716711A1 (en) 1993-09-03 1996-06-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vector for gene therapy of the liver
US5552311A (en) 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5534423A (en) 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
FR2712812B1 (en) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition for the production of therapeutic products in vivo.
IT1271461B (en) 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa ANTI-CD3 / ANTI-EGFR MONOCLONAL ANTI-BODY ANTIBODY, PROCESS FOR PRODUCTION AND ITS USE.
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6312699B1 (en) 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE69520496T2 (en) 1994-05-13 2001-07-12 Chiron Corp METHOD AND COMPOSITIONS AS VEHICLES FOR TARGETED INTRODUCTION OF GENES
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US5570975A (en) 1994-06-27 1996-11-05 Reinert, Sr.; Gary L. Metal foundation push-it and installation apparatus and method
FR2721943B1 (en) 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa ADENOVIRUS COMPRISING A GENE ENCODING A SUPEROXIDE DISMUTASE
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
JPH10508743A (en) 1994-09-09 1998-09-02 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Interleukin-1 type 3 receptor
FR2724846B1 (en) 1994-09-27 1996-12-20 Rhone Poulenc Rorer Sa METHOD OF TREATING CANCER BY REGULATING THE ACTIVITY OF RAS PROTEINS
FR2725726B1 (en) 1994-10-17 1997-01-03 Centre Nat Rech Scient VIRAL VECTORS AND USE IN GENE THERAPY
JP3565859B2 (en) 1994-10-28 2004-09-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Improved adenovirus and uses thereof
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996014837A1 (en) 1994-11-09 1996-05-23 Genetic Therapy, Inc. Gene therapy for hypercholesterolemia
ATE195555T1 (en) 1994-11-29 2000-09-15 Takara Shuzo Co METHOD FOR PRODUCING TRANSFORMED CELLS
FR2727867B1 (en) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS
AUPN107195A0 (en) 1995-02-10 1995-03-09 Withers, Graham Rex Metal matrix forming method and apparatus
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
JPH11511651A (en) 1995-05-10 1999-10-12 イントロヘーネ ベスローテン フェンノートシャップ Improved retroviral vectors particularly suitable for gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
JP2001520511A (en) 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション Targeting adenovirus vector
WO1997038723A1 (en) 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
WO1998011221A2 (en) 1996-09-13 1998-03-19 Dana-Farber Cancer Institute Car, a novel coxsackievirus and adenovirus receptor
CA2266342C (en) 1996-09-25 2010-06-08 Novartis Ag Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
ATE296117T1 (en) 1997-03-07 2005-06-15 Wistar Inst USE OF ADENOVIRAL VECTORS EXPRESSING PDGF OR VEGF TO HEAL TISSUE DEFECTS AND TO INDUCE HYPERVASCULISM IN MAMMAL TISSUES
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
CN1260835A (en) 1997-04-25 2000-07-19 科莱特诺医疗公司 Truncated vegf-related proteins
IL132673A0 (en) 1997-05-08 2001-03-19 Genetic Therapy Inc Gene transfer with adenoviruses having modified fiber proteins
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
WO1999047180A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IT1299201B1 (en) 1998-05-08 2000-02-29 San Raffaele Centro Fond GENETICALLY MODIFIED FIBROBLASTS AND THEIR USE
EP0959136A1 (en) 1998-05-20 1999-11-24 Introgene B.V. Targeted delivery through a cationic amino acid transporter
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
AU6184499A (en) 1998-10-28 2000-05-15 University Of British Columbia, The Organic vanadium(iii) complexes and their use
EP1020529B1 (en) 1998-11-20 2005-06-01 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
IL133032A (en) 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1016726A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
ATE403006T1 (en) 1999-03-04 2008-08-15 Crucell Holland Bv USE OF AN ADENOVIRUS VECTOR FOR TRANSDUCING SYNOVIAL CELLS
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
ATE364707T1 (en) 1999-05-17 2007-07-15 Crucell Holland Bv RECOMBINANT HUMAN ADENOVIRUS SEROTYPE 35
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
WO2001030158A1 (en) 1999-10-28 2001-05-03 Research Association For Improvement Of Wood Quality Creosote oil emulsion and process for producing the same
DE60116513T2 (en) 2000-08-10 2006-09-21 Crucell Holland B.V. ADENOVIRENVEKTOREN FOR THE TRANSDUCTION OF CHONDROCYTES
CA2421864A1 (en) 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
EP1191104A1 (en) 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
PT1497438E (en) 2002-04-25 2010-02-04 Crucell Holland Bv Means and methods for the production of adenovirus vectors
DK1497440T3 (en) 2002-04-25 2008-12-01 Crucell Holland Bv Stable adenoviral vectors and methods of propagation thereof
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
WO2005033320A1 (en) 2003-10-02 2005-04-14 Crucell Holland B.V. Packaging cells for recombinant adenovirus
KR101253363B1 (en) 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 Improved adenoviral vectors and uses thereof
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880102A (en) * 1995-01-17 1999-03-09 Duke University Adenoviral vector system
WO1997000326A1 (en) * 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1998017783A1 (en) * 1996-10-23 1998-04-30 Regents Of The University Of Michigan Improved adenovirus vectors
DE19754103A1 (en) * 1997-12-08 1999-06-10 Hepavec Ag Fuer Gentherapie New packaging cell line for E1-deleted adenovirus
WO1999032647A1 (en) * 1997-12-23 1999-07-01 Introgene B.V. Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
DE19807265A1 (en) * 1998-02-20 1999-08-26 Centeon Pharma Gmbh New adenoviral vector useful for gene therapy
DE19918023A1 (en) * 1999-03-16 2000-09-21 Guenter Cichon Preparation of a liver cell-derived packaging cell line comprises stabile transfection of adenoviral E1 sequences of human hepatoma cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RUMPF H ET AL: "Two domains within the adenovirus type 12 E1A unique spacer have disparate effects on the interaction of E1A with P105- Rb and the transformation of primary mouse cells", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 257, no. 1, 25 April 1999 (1999-04-25), pages 45 - 53, XP002134555, ISSN: 0042-6822 *
SCHIEDNER G ET AL: "EFFICIENT TRANSFORMATION OF PRIMARY HUMAN AMNIOCYTES BY E1 FUNCTIONS OF AD5: GENERATION OF NEW CELL LINES FOR ADENOVIRAL VECTOR PRODUCTION", HUMAN GENE THERAPY, XX, XX, vol. 11, no. 15, 10 October 2000 (2000-10-10), pages 2105 - 2116, XP000974022, ISSN: 1043-0342 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines

Also Published As

Publication number Publication date
PT1349926E (en) 2006-12-29
US6869794B2 (en) 2005-03-22
CA2428739A1 (en) 2002-05-23
JP2004513657A (en) 2004-05-13
WO2002040665A2 (en) 2002-05-23
JP4402881B2 (en) 2010-01-20
US7344883B2 (en) 2008-03-18
US20150010952A1 (en) 2015-01-08
US20030119192A1 (en) 2003-06-26
US20030185801A1 (en) 2003-10-02
AU1856902A (en) 2002-05-27
US9228205B2 (en) 2016-01-05
US6492169B1 (en) 2002-12-10
EP1349926A2 (en) 2003-10-08
US7250293B2 (en) 2007-07-31
CY1105232T1 (en) 2010-03-03
DK1349926T3 (en) 2006-10-30
NZ525997A (en) 2005-10-28
US6974695B2 (en) 2005-12-13
US20050277194A1 (en) 2005-12-15
DE60121471T2 (en) 2007-02-08
US20080199433A1 (en) 2008-08-21
US20130156736A1 (en) 2013-06-20
ES2267864T3 (en) 2007-03-16
EP1349926B1 (en) 2006-07-12
CA2428739C (en) 2010-11-16
AU2002218569B2 (en) 2007-04-05
DE60121471D1 (en) 2006-08-24
ATE332965T1 (en) 2006-08-15
US20030171336A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
WO2002040665A3 (en) Complementing cell lines
Gao et al. State‐of‐the‐art human adenovirus vectorology for therapeutic approaches
Schiedner et al. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production
Eto et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability
Fallaux et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses
CA2477954A1 (en) Means and methods for the production of adenovirus vectors
Randrianarison-Jewtoukoff et al. Recombinant adenoviruses as vaccines
Vogels et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity
Von Seggern et al. A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles
Lanciotti et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates
Barouch Rational design of gene‐based vaccines
WO2000012740A3 (en) Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
CA2161962A1 (en) Adenovirus vectors for gene therapy
AU5152998A (en) Improved adenovirus vectors
WO2003078592A3 (en) Method for the purification, production and formulation of oncolytic adenoviruses
EP0978566A3 (en) Chimaeric adenoviruses
NO20010576L (en) Immunological herpes simplex virus antigens and methods for their use
WO2008095027A3 (en) Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
Fattori et al. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming–boosting with novel adenoviral vectors based on different serotypes
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
WO2001055362A3 (en) Hybrid adeno-retroviral vector for the transfection of cells
Im et al. MVA as a vector for vaccines against HIV-1
Legrand et al. Vaccinia viruses with a serpin gene deletion and expressing IFN-γ induce potent immune responses without detectable replication in vivo
WO2001021201A3 (en) Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
Suzuki et al. Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001996603

Country of ref document: EP

Ref document number: 2428739

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002543660

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 525997

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002218569

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001996603

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 525997

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 525997

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001996603

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002218569

Country of ref document: AU